Brain cancer vaccine - Advanced Biotherapies

Drug Profile

Brain cancer vaccine - Advanced Biotherapies

Alternative Names: Antisense TGF-beta-2 gene therapy

Latest Information Update: 01 Jun 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advanced Biotherapies
  • Class Antisense DNA; Cancer vaccines; Cell therapies; Tumour cell vaccines
  • Mechanism of Action Immunostimulants; Transforming growth factor beta2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Glioblastoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Jun 2006 No development reported - Phase-I for Glioblastoma in USA (SC)
  • 23 Jul 2002 A study has been added to the adverse events and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top